The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|July 7, 2023
- Pharmaceutical Technology's In the Lab eNewsletter, August 2023
- Volume 18
- Issue 8
Eurofins Genomics Blue Heron Launches In-Vitro Transcription mRNA Synthesis Service
Author(s)Grant Playter
Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.
Advertisement
Eurofins Genomics Blue Heron, a biotechnology company specializing in advanced gene synthesis, announced the launch of its in-vitro transcription (IVT) messenger RNA (mRNA) synthesis service on June 29, 2023. According to a company press release, the new synthesis service is designed to offer a comprehensive solution for researchers seeking high-quality, customizable mRNA synthesis with fast turnaround times.
According to the release, the new synthesis service is equipped to handle various applications and includes customizable mRNA synthesis capabilities to meet specific research needs. It is designed for use in molecular biology, drug discovery, vaccine development, and gene therapy, among other fields.
Source: Eurofins Genomics
Articles in this issue
about 3 years ago
Exploring the Skills Gap in Statistical Programming Organizationsabout 3 years ago
Exploring an Intelligent Drug Development Paradigmabout 3 years ago
Microbe Monitoringabout 3 years ago
Roche and Alnylam Strike $2.8 Billion RNAi Dealabout 3 years ago
Bristol Myers Squibb and Evotec Extend Neuroscience Pactabout 3 years ago
Pfizer and Flagship Pioneering Enter Innovation Partnershipabout 3 years ago
Sanofi and Scribe Therapeutics Expands Genomics Collaborationover 3 years ago
Thermo Fisher Scientific Releases Tumoroid Culture Medium KitAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
5